COMP <GO>
RAL vs TMO // RETURN ON INVESTED CAPITAL (ROIC)
Ralliant Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: RAL 4
— TMO 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: TMO
LAST: $67.21 (-4.71%) • MKT CAP: $7.80B
roic
-35.00%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
roic
9.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RAL VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RAL | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.30% | 41.00% | +9.30 | RAL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 9.30% | -44.30 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 30.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.59% | 2.40% | +2.19 | RAL | /fcf-yield <GO> |
| Operating Margin | -57.20% | 17.40% | -74.60 | TMO | /operating-margins <GO> |
| Net Profit Margin | -59.10% | 15.10% | -74.20 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | -4.00% | 3.90% | -7.90 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.14% | 0.24% | -0.10 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.11 | 4.50 | -3.39 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.70% | +0.30 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.1 | 59.1 | -14.01 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.03 | 0.94 | +0.09 | RAL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 36.3x | -15.30 | RAL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.80B | $262.22B | -$254.41B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RAL REV | TMO REV | RAL GROSS % | TMO GROSS % | RAL FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.07B | $44.56B | 50.3% | 44.0% | $358.4M | $6.29B |
| FY 2024 | $2.15B | $42.88B | 51.6% | 44.0% | $420.2M | $7.27B |
| FY 2023 | $2.16B | $42.86B | 44.0% | 44.0% | $364.8M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RAL // BETA 1.03
TMO // BETA 0.94